Home > Boards > US Listed > Medical - Equipment >

Cytosorbents Corporation (CTSO)

Add CTSO Price Alert      Hide Sticky   Hide Intro
Moderator: The_Free_Nebula
Search This Board:
Last Post: 2/13/2016 6:50:41 AM - Followers: 178 - Board type: Free - Posts Today: 0
About CytoSorbents, CytoSorb, and HemoDefend

CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. In 2011, CytoSorb®, the Company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, allowing it to be sold throughout the European Union (E.U.) under the CE Mark, to be used in clinical situations where cytokines are elevated. The goal of the CytoSorb® cytokine filter is to reduce "cytokine storm" in critically-ill patients that could otherwise lead to deadly inflammation, multiple organ failure, immune dysfunction, and often death in common illnesses such as sepsis, trauma, burn injury, acute respiratory distress syndrome, and pancreatitis. The CytoSorb® filter has demonstrated statistically significant reductions in mortality in septic patients at high risk of death in early studies and is now being sold in Germany, Austria and Switzerland for the treatment of critical care illnesses, with availability in other E.U. countries planned in the future, assuming adequate and timely funding, and continued positive results from clinical studies.

HemoDefend is a development-stage blood purification technology platform for the blood transfusion industry intended to reduce transfusion reactions and safeguard the quality and safety of the blood supply. The HemoDefend technology utilizes the Company's polymer bead technology to remove many substances, such as antibodies, free hemoglobin and inflammatory mediators that can cause potentially serious and sometimes fatal transfusion reactions.

CytoSorb® and HemoDefend are just two of a number of different polymers the Company has designed for various medical applications, including improved dialysis, reduction of post-surgical complications in cardiac surgery, treatment of inflammatory and autoimmune disorders, radio-imaging contrast removal in imaging and interventional radiology procedures, and the treatment of rhabdomyolysis, drug overdose, and others. Additional information is available for download on the Company's website:


CytoSorb® - A First-in-Class Cytokine Filter Approved in the European Union


CytoSorb® is a potentially breakthrough critical care immunotherapy that attempts to address one of the most challenging unmet medical needs in medicine…the ability to prevent or mitigate multiple organ failure - the leading cause of death in the intensive care unit (ICU) from any cause.

In response to life-threatening conditions such as sepsis and infection, trauma, serious burn injuries, severe lung injury, and pancreatitis, the body frequently overreacts and produces a massive excess of cytokines, or “cytokine storm”. Cytokines normally help the body cope with injury, but at these levels, cytokine storm is toxic to the body, driving severe inflammation and a cascade of pathophysiologic changes in the body that cause cell damage, organ failure and often death. It follows that reduction of cytokine storm may limit this cascade of events, thereby reducing the severity of illness, and helping patients recover and survive. Until recently, however, there were no effective ways to reduce cytokine storm broadly.

CytoSorb® is a first-in-class extracorporeal cytokine filter, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated. It is compatible with standard hemodialysis machines and blood pumps found in most hospitals. Blood is pumped out of the body, through the CytoSorb® cartridge that contains the company’s proprietary blood compatible porous polymer beads, and the “purified” blood is recirculated back to the patient. In a six hour period, a patient's entire blood volume can be treated approximately 20 times.

CytoSorb® is clinically proven to reduce cytokine storm in the company's multi-center, randomized, controlled European Sepsis Trial conducted in Germany. Treatment was safe and well-tolerated in more than 300 human treatments in very sick patients with the worst forms of sepsis and lung injury, and treatment has been safe in nearly 1,500 human treatments overall. Early data suggests that CytoSorb® can reduce organ injury and improve survival in patients at high risk of cytokine injury, particularly those patients with very high cytokine levels, and patients older than age 65.

CytoSorb® has now been used successfully in many conditions where deadly inflammation can lead to organ injury and failure. We are seeing strong interest in the following clinical applications:


There are more than 100 key opinion leaders in Germany, Austria, and Switzerland (our direct sales territories) who are either using or committed to using CytoSorb in clinical practice or clinical studies. More than 30 investigator-initiated studies in a diverse set of applications are being planned, with many already enrolling patients. In the United States, the U.S. Air Force is funding a 30-patient, FDA-approved randomized controlled human trauma pilot study.

As these other independent studies progress, CytoSorbents collaborates with Dr. John Kellum at the University of Pittsburgh Medical Center, and is sponsoring clinical studies in the area of severe sepsis and septic shock, the result of an overzealous immune response to a severe infection such as pneumonia or a ruptured appendix. Severe sepsis and septic shock are collectively a top ten cause of death worldwide, afflicting approximately 27 million people annually, killing approximately 1 in 3 patients despite the best medical care. CytoSorbents is conducting clinical trials in Europea and currently has an FDA-approved IDE application to run a small sepsis trial in the U.S.. The company will look to conduct a U.S. pivotal sepsis study in the future as a key step towards U.S. FDA approval.

Because of the versatility of CytoSorb®, there are many other potential applications of the technology outside of critical care medicine as well. In particular, CytoSorb® has been used many times intraoperatively during open heart surgery, where the heart must be stopped in order to operate on it, while the blood is pumped outside of the body by a heart-lung machine that oxygenates the blood and pumps it back to the rest of the body. This procedure can result in the production of inflammatory mediators such as cytokines, as well as hemolysis and the release of free hemoglobin into the blood. This can result in inflammation and post-operative complications such as failure to wean from mechanical ventilation and kidney failure. There are more than 1 million open heart surgeries each year in the U.S. and E.U. combined, with an addressable market of more than $1 billion for CytoSorb®.

Another application is in cancer immunotherapy. Cancer cachexia is a wasting condition that occurs in most cancers that leads to rapid uncontrolled weight loss, anorexia, and physical debilitation. Patients lose the physical reserve needed to tolerate treatment and fight the cancer. Because CytoSorb® can remove a broad range of cytokines and other inflammatory mediators that drive cancer cachexia, it may be very helpful in this condition. CytoSorbents is exploring this application, as well as the use of CytoSorb® as a primary cancer immunotherapy to kickstart the immune system to attack cancer, with researchers at the University of Pennsylvania School of Veterinary Medicine.

CytoSorb® is being sold for clinical use in the European Union and in countries outside of the European Union that accept European CE Mark approval such as India, Russia, Turkey and others. The total addressable market for CytoSorb® in critical care applications such as sepsis, burn injury, trauma, ARDS, pancreatitis and other diseases is estimated at $10-15 Billion in the U.S. and Europe alone.


From Shareholder's Letter

Goals for 2014

We have laid out an ambitious, yet potentially achievable, agenda for the next two years. Some of our highest priorities are:

  • Greater awareness of our story and technology through increased media exposure and improved investor relations
  • Revenue growth and increased product adoption in our direct sales territories
  • Distributor agreements for CytoSorb in Europe and elsewhere
  • Strategic partnerships for our pipeline products
  • Non-dilutive funding from grants and other programs
  • Commencement of a U.S. based trial
  • Clinical data and new clinical applications with data being presented at key scientific conferences
  • Improving liquidity and institutional sponsorship of our stock with potential up-listing to a national stock exchange

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
CTSO News: Current Report Filing (8-k) 02/09/2016 03:23:40 PM
CTSO News: CytoSorbents to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference 02/04/2016 07:00:00 AM
CTSO News: CytoSorbents Receives $325,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Progr... 02/01/2016 07:00:00 AM
CTSO News: CytoSorbents to Present at the 18th Annual BIO CEO & Investor Conference 01/28/2016 07:00:00 AM
CTSO News: CytoSorbents Appoints Dr. Volker Humbert as Senior Manager of Clinical Affairs 01/21/2016 08:00:00 AM
#6174  Sticky Note From Yahoo MB-Updated Cytosorbents Overview andy55q 12/19/14 10:40:16 AM
#7502   CytoSorbents Teams With INTENSIVMED for CytoSorb® Distribution in Russia andy55q 02/13/16 06:50:41 AM
#7501   I see on their articles page there is orangecat 02/12/16 09:47:13 AM
#7500   CytoSorb - Polymer-based system for adsorbing cytokines andy55q 02/11/16 05:50:02 PM
#7499   Sweden registration andy55q 02/11/16 06:45:18 AM
#7498   Case of the week 05/2016 andy55q 02/10/16 07:27:49 AM
#7497   Interesting Daily Mail article about sepsis. aculeus 02/08/16 08:42:03 PM
#7496   PARTICIPANTS Austria 1 Belgium 4 Finland 2 France 3 Germany 7 Nethe andy55q 02/08/16 11:09:38 AM
#7495   Dear CytoSorb user, we are pleased to invite andy55q 02/06/16 09:40:26 PM
#7494   User Meeting Participants andy55q 02/05/16 07:40:16 AM
#7493   Don't read it!! andy55q 02/04/16 03:38:54 PM
#7492   Who cares? All of the stuff that is BuyMyAsk 02/04/16 10:19:35 AM
#7491   NEWS -- CytoSorbents to Present at Source Capital Paulness 02/04/16 09:04:17 AM
#7490   We have 3 people from Russia attending the andy55q 02/03/16 02:50:39 PM
#7489   Because I am not!! andy55q 02/03/16 02:46:05 PM
#7488   Andy why dont you have an intellectual conversation BuyMyAsk 02/03/16 09:15:58 AM
#7487   Updated FAQ page andy55q 02/03/16 08:26:57 AM
#7486   Update Investors Presentation February 2016 andy55q 02/02/16 07:39:16 AM
#7485   Klinik für Anästhesiologie, Intensivmedizin und Paliativmedizin, Carl-Thiem-Klin andy55q 02/02/16 07:19:33 AM
#7484   A drop on a hot stone..... SABAI 02/01/16 10:24:05 AM
#7483   NEWS -- CytoSorbents Receives $325,000 in Non-Dilutive Funding Paulness 02/01/16 09:47:18 AM
#7482   • 27.01.2016 The successful use of cytokines Cytosorb andy55q 01/30/16 09:30:09 AM
#7481   From Yahoo MB techxen • 12 hours ago andy55q 01/30/16 09:04:45 AM
#7480   The above message describe the case of a valeer15 01/30/16 04:01:47 AM
#7479   • 27.01.2016 ???????? ?????????? ????????? ????????? Cytosorb ? andy55q 01/29/16 12:05:43 PM
#7478   This new trial is being conducted at University andy55q 01/28/16 09:26:28 PM
#7477   On 40K vol. ? LOL....peanuts imo. SABAI 01/28/16 02:09:55 PM
#7476   It would be interesting to see what the vinovista 01/28/16 01:53:48 PM
#7475   NEWS -- CytoSorbents to Present at the 18th Paulness 01/28/16 09:01:12 AM
#7474   World Sepsis Day Facebook page info. andy55q 01/28/16 08:02:56 AM
#7473   Case of the week 1/27/2016 andy55q 01/27/16 07:31:58 AM
#7472   Teen girl nearly dies from toxic shock syndrome andy55q 01/21/16 12:18:29 PM
#7471   3rd International Users’ Meeting andy55q 01/21/16 10:57:25 AM
#7470   NEWS -- CytoSorbents Appoints Dr. Volker Humbert as Paulness 01/21/16 08:39:33 AM
#7469   CytoSorb Therapy andy55q 01/20/16 05:37:31 PM
#7468   From Yahoo MB andy55q 01/20/16 05:34:04 PM
#7467   Where will CTSO be when S&P is 1570 ? SABAI 01/20/16 12:21:44 PM
#7466   The entire bio-tech sector is just get CRUSHED BuyMyAsk 01/20/16 11:09:55 AM
#7465   26th Symposium Intensive Medicine + Intensive Care 2016 andy55q 01/20/16 10:31:36 AM
#7464   I am very startled by this. Dr. BuyMyAsk 01/19/16 04:33:53 PM
#7463   Boy oh boy ... Who or what needs SABAI 01/19/16 04:13:22 PM
#7462   Baystate Medical (REFRESH) details andy55q 01/18/16 08:53:58 AM
#7461   37th International Symposium St. Anton andy55q 01/17/16 01:00:30 PM
#7460   Looks more like 3-4$. Crazy.......gla SABAI 01/15/16 09:55:38 AM
#7459   94 PARTICIPATING CLINICAL CENTERS- Cytosorb Registry andy55q 01/14/16 02:40:18 PM
#7458   Buyers will come soon. BuyMyAsk 01/12/16 12:01:24 PM
#7457   7-8$ soon. All imo. Gla SABAI 01/12/16 11:29:02 AM
#7456   I could be wrong, but I think the BuyMyAsk 01/12/16 11:02:10 AM
#7455   The revenue is promising, good to see growth pharmeng 01/11/16 06:11:09 PM
#7454   way oversold The_Free_Nebula 01/11/16 05:05:56 PM
#7453   I think there are a good amount of BuyMyAsk 01/11/16 04:08:13 PM